Explore more publications!
St. Vincent & Grenadines Health Press
Got News to Share?

St. Vincent & Grenadines Health Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on St. Vincent & Grenadines Health Press.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 8, 2025

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
December 8, 2025

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

Indeterminate GlobeNewswire
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
December 8, 2025

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Indeterminate GlobeNewswire
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
December 8, 2025

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

Indeterminate GlobeNewswire
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
December 8, 2025

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

Indeterminate GlobeNewswire
HealthLynked Appoints Duncan McGillivray as Chief Operating Officer to Accelerate National Expansion and Nasdaq Uplisting Strategy
December 8, 2025

HealthLynked Appoints Duncan McGillivray as Chief Operating Officer to Accelerate National Expansion and Nasdaq Uplisting Strategy

Indeterminate GlobeNewswire
Wicked Reserve Dispensary Expands Range with New Refrigerated THC Beverage Section
December 8, 2025

Wicked Reserve Dispensary Expands Range with New Refrigerated THC Beverage Section

Indeterminate GlobeNewswire
Rehab 4 Addiction CEO Releases New Article Sharing Effective Tips for Going Sober This December, And Actually Enjoying It
December 8, 2025

Rehab 4 Addiction CEO Releases New Article Sharing Effective Tips for Going Sober This December, And Actually Enjoying It

Indeterminate GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 8, 2025

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Indeterminate GlobeNewswire
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
December 8, 2025

Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026

Indeterminate GlobeNewswire
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
December 8, 2025

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

Indeterminate GlobeNewswire
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
December 8, 2025

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Indeterminate GlobeNewswire
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 8, 2025

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Indeterminate GlobeNewswire
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
December 8, 2025

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Indeterminate GlobeNewswire
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
December 8, 2025

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Indeterminate GlobeNewswire
Kraig Biocraft Laboratories Secures Usage Rights to Strategic Government-Owned Mulberry Gardens to Support Major Spider Silk Production Expansion
December 8, 2025

Kraig Biocraft Laboratories Secures Usage Rights to Strategic Government-Owned Mulberry Gardens to Support Major Spider Silk Production Expansion

Indeterminate GlobeNewswire
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
December 8, 2025

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment

Indeterminate GlobeNewswire
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
December 8, 2025

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Indeterminate GlobeNewswire
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
December 8, 2025

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Indeterminate GlobeNewswire
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
December 8, 2025

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Indeterminate GlobeNewswire
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
December 8, 2025

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions